Key result
Paricalcitol reverses cardiac dysfunction and improves LVEF in metabolic syndrome rats by enhancing mitochondrial fusion.
Why the study?
Whether activation of the vitamin D receptor can attenuate heart failure and underlying metabolic phenotype required investigation.
Does paricalcitol improve cardiac dysfunction in a rat model of metabolic syndrome?
Does paricalcitol improve cardiac dysfunction in a rat model of metabolic syndrome?
Paricalcitol reverses cardiac dysfunction in a rat model of metabolic syndrome by enhancing mitochondrial fusion, suggesting a repurposing potential for heart failure.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in metabolic syndrome models; human trials needed before any clinical consideration.
Objectives . Transition from cardiac hypertrophy to failure involves adverse metabolic reprogramming involving mitochondrial dysfunction. We have earlier shown that vitamin D deficiency induces heart failure, at least in part, through insulin resistance. However, whether activation of vitamin D receptor (VDR) can attenuate heart failure and underlying metabolic phenotype requires investigation. Thus, we aimed to assess the cardioprotective potential of paricalcitol, a vitamin D receptor‐activator, against cardiac hypertrophy and failure in high‐fat high‐fructose‐fed rats. Methods . Male Sprague Dawley rats were fed control (Con) or high‐fat high‐fructose (HFHFrD) diet for 20 weeks. After 12 weeks, rats from HFHFrD group were divided into the following: HFHFrD, HFHFrD+P (paricalcitol i.p. 0.08 μ g/kg/day) and HFHFrD+E (enalapril maleate i.p. 10 mg/kg/day). Intraperitoneal glucose tolerance test, blood pressure measurement, and 2D echocardiography were performed. Cardiac fibrosis was assessed by Masson’s trichrome staining of paraffin‐embedded heart sections. Mitochondrial DNA and proteins, and citrate synthase activity were measured in rat hearts. VDR was silenced in H9c2 cardiomyoblasts, and immunoblotting was performed. Results . Paricalcitol improved glucose tolerance, serum lipid profile, and blood pressure in high‐fat high‐fructose‐fed rats. Paricalcitol reduced cardiac wall thickness and increased ejection fraction in high‐fat high‐fructose‐fed rats but had no effect on perivascular fibrosis. PGC1‐ α was upregulated in the HFHFrD+P group compared to the HFHFrD group, but there was no significant difference in mitochondrial content. Citrate synthase activity was significantly higher in the HFHFrD+P group compared to the HFHFrD group. Rat hearts of the HFHFrD+P group had significantly higher expression of mitofusins. H9c2 cells with VDR knockdown showed significantly lower expression of Mfn2. Improvement in the HFHFrD+P group was comparable with that in the HFHFrD+E group. Conclusions . Paricalcitol reverses cardiac dysfunction in rats with metabolic syndrome by enhancing mitochondrial fusion. We demonstrate repurposing potential of the drug currently used in end‐stage kidney disease.
No takes yet. Share an insight, caveat, or question.
Nizami et al. (2022) studied Metabolic syndrome-associated heart failure. Paricalcitol vs. High-fat high-fructose diet alone and enalapril maleate was evaluated on Cardiac hypertrophy, ejection fraction, and metabolic parameters. Paricalcitol reversed cardiac dysfunction, reduced wall thickness, and increased ejection fraction in rats with metabolic syndrome by enhancing mitochondrial fusion.
Synapse has enriched 10 related papers. Consider them for comparative context: